| Autor: |
Schenkelaars EJ; CIBA-GEIGY Corporation, Pharmaceuticals Division, Summit, NJ 07901., Singh HN, Goldberg RL, Doughty JR, Peppard J, DiPasquale G, Quagliata F |
| Jazyk: |
angličtina |
| Zdroj: |
Agents and actions [Agents Actions] 1991 Sep; Vol. 34 (1-2), pp. 66-9. |
| DOI: |
10.1007/BF01993240 |
| Abstrakt: |
We have shown that during the developing phase of adjuvant disease (AD) in rats the expression of MHC class II (Ia) antigens on blood monocytes (BM) was enhanced. The results of a study in established AD are reported now. Four agents were tested: indomethacin and diclofenac-sodium (1 mg/kg/day); levamisole and prinomide (10 mg/kg/day), administered orally from day 18-31 after induction of AD. We assessed the following BM parameters: Ia expression, interleukin-1 (sIL-1) production, and membrane bound IL-1 (mIL-1). In AD Ia expression was enhanced, no changes occurred in mIL-1 or sIL-1. Indomethacin treatment reduced sIL-1 production, levamisole Ia expression and mIL-1 activity, prinomide all three parameters measured and diclofenac, though clinically effective, none. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
